The Brazil CMO/CDMO ecosystem is expected to surge at a CAGR of 2.7% in the forecast period 2023 to 2033. Its value is projected to increase from US$ 697.93 million in 2023 to US$ 907.67 million by 2033. The Brazil CMO/CDMO business was valued at US$ 679.10 million at the end of 2022 and is anticipated to exhibit a y-o-y growth of 2.8 % in 2023.
| Attributes | Key Insights |
|---|---|
| Brazil CMO/CDMO Business Size (2022A) | US$ 679.10 million |
| Brazil CMO/CDMO Business Estimated Revenue (2023E) | US$ 697.93 million |
| Brazil CMO/CDMO Business Projected Revenue (2033F) | US$ 907.67 million |
| Value-based CAGR (2023 to 2033) | 2.7% |
Brazil is projected to be one of the most prominent pharmaceutical sectors in Latin America. The surging aging population, rising healthcare costs, and increased public knowledge of healthcare have all contributed to a steady increase in the demand for pharmaceuticals in Brazil.
The government of Brazil has implemented stringent rules to promote regional pharmaceutical production. This includes policies, including tax breaks and privileges for domestically produced goods.
The Brazil CMO/CDMO business has placed a substantial emphasis on the manufacturing of biologics and biosimilars. These sophisticated treatments frequently call for specialist production skills.
For contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) operating in Brazil, compliance with international quality standards, such as Good Manufacturing Practices (GMP), is essential. Both domestic and international sales depend on compliance with regulatory regulations.
Biotech and pharmaceutical companies in Brazil are increasingly using CMOs and CDMOs to handle their manufacturing requirements. The necessity for flexible production capacity, access to specialist knowledge, and cost-effectiveness are a handful of the driving forces behind this outsourcing trend.
CMO/CDMO companies are set to offer manufacturing services to the biotechnology, pharmaceutical, and other industries, as well as help with the production of medical equipment. CMOs are also expected to provide their resources, knowledge, and facilities to make goods for their customers.
The CMO and CDMO sector has seen rapid expansion in recent years. The pharmaceutical and biotechnology industries have seen a rise in the outsourcing of production and development services owing to the advantages of cost savings, flexibility, and access to specialized knowledge.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The Brazil CMO/CDMO business recorded a decent CAGR of 2.0% in the historical period from 2018 to 2022. The value for the CMO/CDMO business in Brazil was around 1.2% of the total US$ 56,660.60 million of the global CMO/CDMO business.
The growing pharmaceutical sector is the main factor spurring the Brazil CMO/CDMO business landscape. Increasing approval of manufacturing facilities is set to drive growth.
The total production capacity in Brazil rises as more manufacturing facilities are approved. The increased demand for outsourcing services would enable CMOs and CDMOs to take on additional clients and projects.
The approval of multiple manufacturing facilities, such as those for sterile injectables, biologics, or specialized formulations, can increase the variety of services provided by CMOs and CDMOs. Due to this variety, pharmaceutical companies can select partners who meet their particular requirements.
Manufacturing facilities would become more competitive in the global business landscape as they receive approval. CMOs/CDMOs that can show compliance with international regulatory standards would draw clients from other nations looking for dependable manufacturing partners in addition to Brazil.
The Brazil CMO/CDMO ecosystem has begun to place a lot of emphasis on the manufacturing of biologics and biosimilars. The complexity of these products frequently necessitates specialized production capabilities, and this business category has seen tremendous expansion.
The government of Brazil has also started several programs to encourage expansion in the biotechnology and pharmaceutical sectors. These include tax breaks, research grants, and other forms of assistance to promote industrial investment and innovation.
CMOs and CDMOs in Brazil have started to focus more on research & development services and offering their experience in technological development. They are also aiming to understand analytical testing and process optimization in addition to typical manufacturing services
The table below provides the latest trends observed in the Brazil CMO/CDMO space, growth obstacles, and upcoming opportunities. Business strategies for pushing CMO/CDMO sales in Brazil would enable stakeholders to invest in the right area and gain profit.
| Attributes | Key Factors |
|---|---|
| Latest Trends |
|
| Upcoming Opportunities |
|
| Challenges |
|
Principal Consultant
The table below shows the share of the top 5 countries for the review period from 2023 to 2033. South and North Brazil are expected to remain dominant by exhibiting CAGRs of 4.5% and 4.9%, respectively. The Central-west and Northeast Brazil are projected to follow with CAGRs of 3.8% and 3.1%, respectively.
Growth Outlook by Key Region
| Regions | Value CAGR |
|---|---|
| Southeast Brazil | 2.3% |
| Northeast Brazil | 3.1% |
| Central-west Brazil | 3.8% |
| South Brazil | 4.5% |
| North Brazil | 4.9% |
Growth in Southeast Brazil’s pharmaceutical sector is expanding steadily. Due to population expansion and improved access to healthcare, there is an increase in local demand for pharmaceuticals and other medical products.
The Southeast area of Brazil is benefiting from initiatives the government has put in place to encourage pharmaceutical business expansion. This includes financial incentives and tax breaks for businesses setting up shop in the region.
Southeast Brazil dominated the CMO/CDMO business and generated a 68.6% share in 2022. It is projected to continue experiencing high growth throughout the forecast period.
The economic center of Brazil is in the southeast, which is home to important cities, such as Sao Paulo and Rio de Janeiro. It is a popular site for CMOs and CDMOs to serve these clients because of its significant industrial base and the large number of pharmaceutical and biotech companies that call it home.
Prestigious universities and research institutions in Southeast Brazil offer a skilled labor pool and chances for collaboration between CMOs/CDMOs and academia on research & development projects. Also, several CMOs/CDMOs based in Southeast Brazil have expanded their operations globally, enabling them to serve clients both domestically and internationally.
A handful of states in Northeast Brazil, such as Pernambuco, have taken special initiatives to draw in investments in the fields of biotechnology and life sciences. This has caused a cluster of biotech businesses to expand, opening doors for CMOs and CDMOs that focus on biologics.
Biotechnology and pharmaceutical research and development have received more attention in the region. This involves the development of formulations, analytical testing, and process optimization, areas in which CMOs and CDMOs can be particularly skilled.
Northeast Brazil dominates the Brazil CMO/CDMO business and held a 19.8% share in 2022. It is projected to continue experiencing high growth throughout the forecast period. Northeast Brazil has special environmental features or natural resources that make biopharmaceutical research and development possible.
Northeast Brazil is also the perfect location for companies focused on biotech and their manufacturing partners backed by these resources. Also, the region is home to eminent research facilities and academic hubs with a focus on biotechnology and pharmaceuticals.
They can promote cooperation between these institutions and CMOs/CDMOs. Such collaborations are frequently necessary to expand research and development initiatives.
Central-west Brazil held about a 5.1% share of the Brazil CMO/CDMO business in 2022. It is projected to increase during the forecast period.
Central-west Brazil's center geographic location offers a logistical advantage, enabling effective pharmaceutical product distribution to multiple regions across Brazil and adjacent nations. For CMOs and CDMOs aiming to serve a large space, this can be a crucial draw.
Investments in infrastructure, including transportation networks and industrial parks, can further enhance the region's attractiveness for pharmaceutical manufacturing and supply chain operations. The government supports domestic medicinal product production.
CMOs and CDMOs in the region would have the chance to serve the home ecosystem and export goods. Several colleges and research facilities in Central-west Brazil offer a pool of qualified workers in fields related to pharmaceutical development and manufacturing. CMOs and CDMOs can benefit from this in terms of hiring new personnel.
The table below signifies leading sub-categories under product, expression, and company size categories in the Brazil CMO/CDMO business. Stand-alone services are expected to dominate the ecosystem for Brazil CMO/CDMO at a CAGR of 3.4% by 2033. Under the company size category, the mid-sized segment is projected to lead the Brazil CMO/CDMO space with a CAGR of 2.3% by 2033.
Growth Outlook by Key Segments
| Segment | Value CAGR |
|---|---|
| Stand-alone Services (Services) | 3.4% |
| API Substrate (Product) | 1.9% |
| Mid-sized (Company Size) | 2.3% |
| Mammalian (Expression System) | 2.7% |
| Commercial (Scale of Operation) | 2.9% |
Stand-alone services under the service category held a share of 42.5% in 2022. It is expected to remain at the forefront over the forecast period.
Stand-alone services focus on specific aspects of drug development and manufacturing, such as formulation development, analytical testing, or sterile manufacturing. This specialization can attract companies seeking expertise in a particular area.
Companies decide to use stand-alone services to cut costs by outsourcing only a portion of the production or development of drugs while maintaining control over the remaining portions. This factor is anticipated to lead the stand-alone service segment in the Brazil CMO/CDMO business.
API substrate under the product category held a considerable share of 41.4% in 2022. The main components of pharmaceutical formulations are APIs.
APIs, often referred to as the dynamic components of medications, underlie their therapeutic effectiveness. The process of crafting APIs holds a pivotal role in the production of pharmaceuticals, marking a critical step in the journey of creating therapeutic solutions.
Pharmaceutical companies find it more affordable to outsource API production. The volume and efficiency of CMOs and CDMOs would allow them to create APIs more cheaply than in-house labs.
For the manufacturing of biologics, such as monoclonal antibodies, recombinant proteins, and vaccines, mammalian expression systems are frequently chosen. Due to their success in treating a wide range of ailments, biologics have grown in terms of popularity in the operating of the pharmaceutical sector.
Mammalian expression systems are set to be necessary for the manufacturing of several advanced and sophisticated medicines, including cell and gene therapies. These treatments are projected to make up a rapidly expanding area for pharmaceuticals. This factor is expected to stimulate the mammalian segment over the forecast timeline.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Geographic expansions are a priority for leading CMO/CDMO companies in Brazil as they work to create new product lines and expand their global consumer base. Expansion and acquisition among key companies or brands is the leading strategy of manufacturers such as Catalent and Fragon.
They aim to enhance their presence in the business landscape and compete with other players during the forecast period. Following are a handful of recent developments:
For instance,
| Attribute | Details |
|---|---|
| Brazil CMO-CDMO Revenue (2022) | US$ 679.10 million |
| Projected Brazil CMO-CDMO Revenue (2033) | US$ 907.67 million |
| Value-based CAGR (2023 to 2033) | 2.7% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Business Analysis | Value (US$ million) |
| Key Regions Covered | North Brazil; Northeast Brazil; Central-west Brazil; Southeast Brazil; and South Brazil |
| Key Segments Covered | Services, Product, Expression System, Company Size, Scale of Operation, Region |
|
Key Companies Profiled |
Lonza AG; Unither Pharmaceuticals; Catalent Inc.; Fagron; Eurofarma; Pfizer CentreOne; Patheon N.V. (Thermo Fisher Scientific, Inc.); NUVISAN; Societal CDMO; Bio-Manguinhos; Biotimize; Pierre Fabre group; Ajinomoto Co., Inc. |
Brazil was valued at around US$ 679.10 million in 2022.
Brazil is set to reach a valuation of around US$ 907.67 million by 2033.
The API substrate segment held around 41.4% share in 2022.
Brazil's CMO/CDMO space increased at a 2.0% CAGR from 2018 to 2022.
The Brazil CMO/CDMO business is set to reach US$ 697.93 million by 2023.
Southeast Brazil CMO/CDMO business held a 68.6% share in 2022.
Lonza AG and Unither Pharmaceuticals are the key exporters of CMO/CDMO in Brazil.
1. Executive Summary
1.1. Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Overview
2.1. Coverage / Taxonomy
2.2. Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Trends
3.1. Key Trends
4. Value Added Insights
4.1. Service Adoption Analysis/Usage Analysis
4.2. Overview of CRO and CDMO Services
4.3. Role of Contract Service Providers
4.4. Overview of CDMO with a Wide Array of Dosage Form Capabilities
4.5. Regulatory Scenario
4.6. Latest Deals
4.7. PESTLE Analysis
4.8. Porter’s Analysis
4.9. Pharma Services Supply Chain Analysis
4.10. Value Chain Analysis
5. Background
5.1. Macro-Economic Factors
5.1.1. GDP Growth Outlook
5.1.2. Research and Development Funding by Region
5.1.3. Research and Development Funding by Country
5.1.4. Pharmaceutical Spending, By Country
5.1.5. Global CMO-CDMO Sales
5.2. Forecast Factors - Relevance and Impact
5.2.1. Historic Growth of Key Players
5.2.2. Consolidation Activities
5.2.3. Increasing Research and Development Activities
5.2.4. Increased Funding and Support from Government
5.2.5. CMO/CDMO Services Adoption Rates
5.2.6. Increasing Number of Diagnostics Testing and Development
5.2.7. Regulatory Imposition
5.2.8. Increase in Number of Clinicians and Specialists
5.3. Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Demand Value or Size (US$ million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
6.1. Historical Value (US$ million) Analysis, 2018 to 2022
6.2. Current and Future Value (US$ million) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Sales Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
7.1. Introduction / Key Findings
7.2. Historical Size (US$ million) Analysis By Services, 2018 to 2022
7.3. Current and Future Size (US$ million) Analysis and Forecast By Services, 2023 to 2033
7.3.1. Stand-Alone Services
7.3.1.1. Cell Line Development
7.3.1.2. Development and Bio Manufacturing
7.3.1.3. Analytical Services
7.3.1.4. Fill Finish
7.3.1.5. Packaging
7.3.1.6. Clinical Supply Services
7.3.2. Integrated Development
7.3.3. Scale-up and Tech Transfer
7.3.4. Technology and Innovation
7.3.5. Quality Control and Quality Assurance
7.3.6. Regulatory Assistance
7.4. Attractiveness Analysis By Services
8. Sales Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
8.1. Introduction / Key Findings
8.2. Historical Size (US$ million) By Product, 2018 to 2022
8.3. Current and Future Size (US$ million) Analysis and Forecast By Product, 2023 to 2033
8.3.1. API Substrate
8.3.2. Large Molecule
8.3.2.1. Monoclonal Antibodies
8.3.2.2. Antibody Fragments
8.3.2.3. Recombinant Therapeutic Proteins
8.3.2.4. Viral Vector
8.3.2.5. Cell and Gene Therapy
8.3.2.6. Vaccine
8.3.2.7. Peptides
8.3.2.8. Antibody Drug Conjugates (ADCs)
8.3.3. Small Molecule
8.4. Attractiveness Analysis By Product
9. Sales Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
9.1. Introduction / Key Findings
9.2. Historical Size (US$ million) By Expression System, 2018 to 2022
9.3. Current and Future Size (US$ million) Analysis and Forecast By Expression System, 2023 to 2033
9.3.1. Mammalian
9.3.2. Microbial
9.3.2.1. Bacteria
9.3.2.2. Yeast
9.4. Attractiveness Analysis By Expression System
10. Sales Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
10.1. Introduction / Key Findings
10.2. Historical Size (US$ million) By Company Size, 2018 to 2022
10.3. Current and Future Size (US$ million) Analysis and Forecast By Company Size, 2023 to 2033
10.3.1. Small
10.3.2. Mid-sized
10.3.3. Large
10.3.4. Very Large
10.4. Attractiveness Analysis By Company Size
11. Sales Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
11.1. Introduction / Key Findings
11.2. Historical Size (US$ million) By Scale of Operation, 2018 to 2022
11.3. Current and Future Size (US$ million) Analysis and Forecast By Scale of Operation, 2023 to 2033
11.3.1. Preclinical
11.3.2. Clinical
11.3.2.1. Phase I
11.3.2.2. Phase II
11.3.2.3. Phase III
11.3.3. Commercial
11.4. Attractiveness Analysis By Scale of Operation
12. Sales Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Size (US$ million) Trend Analysis by Region, 2018 to 2022
12.3. Current and Future Size (US$ million) Analysis and Forecast by Region, 2023 to 2033
12.3.1. North
12.3.2. Northeast
12.3.3. Central-west
12.3.4. Southeast
12.3.5. South
12.4. Attractiveness Analysis By Region
13. Business: Cross Section Analysis-Product Vs Services
13.1. Historical Size (US$ million) Trend Analysis by Product Vs Services, 2018 to 2022
13.2. Current and Future Size (US$ million) Analysis and Forecast by Product Vs Services, 2023 to 2033
13.2.1. API Substrate
13.2.1.1. Stand-Alone Services
13.2.1.2. Integrated Development
13.2.1.3. Scale-Up and Tech Transfer
13.2.1.4. Technology and Innovation
13.2.1.5. Quality Control and Quality Assurance
13.2.1.6. Regulatory Assistance
13.2.2. Large Molecule
13.2.2.1. Stand-Alone Services
13.2.2.2. Integrated Development
13.2.2.3. Scale-Up and Tech Transfer
13.2.2.4. Technology and Innovation
13.2.2.5. Quality Control and Quality Assurance
13.2.2.6. Regulatory Assistance
13.2.3. Small Molecule
13.2.3.1. Stand-Alone Services
13.2.3.2. Integrated Development
13.2.3.3. Scale-Up and Tech Transfer
13.2.3.4. Technology and Innovation
13.2.3.5. Quality Control and Quality Assurance
13.2.3.6. Regulatory Assistance
14. North Sales Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Size (US$ million) Analysis Trend Analysis by Taxonomy, 2018 to 2022
14.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2023 to 2033
14.3.1. By Service
14.3.2. By Product
14.3.3. By Expression System
14.3.4. By Company
14.3.5. By Scale of Operation
14.4. Attractiveness Analysis
14.4.1. By Service
14.4.2. By Product
14.4.3. By Expression System
14.4.4. By Company
14.4.5. By Scale of Operation
14.5. Drivers and Restraints - Impact Analysis
15. Northeast Sales Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Size (US$ million) Trend Analysis by Taxonomy, 2018 to 2022
15.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2023 to 2033
15.3.1. By Service
15.3.2. By Product
15.3.3. By Expression System
15.3.4. By Company
15.3.5. By Scale of Operation
15.4. Attractiveness Analysis
15.4.1. By Service
15.4.2. By Product
15.4.3. By Expression System
15.4.4. By Company
15.4.5. By Scale of Operation
15.5. Drivers and Restraints - Impact Analysis
16. Central-west Sales Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Size (US$ million) Trend Analysis by Taxonomy, 2018 to 2022
16.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2023 to 2033
16.3.1. By Service
16.3.2. By Product
16.3.3. By Expression System
16.3.4. By Company
16.3.5. By Scale of Operation
16.4. Attractiveness Analysis
16.4.1. By Service
16.4.2. By Product
16.4.3. By Expression System
16.4.4. By Company
16.4.5. By Scale of Operation
16.5. Drivers and Restraints - Impact Analysis
17. Southeast Sales Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Size (US$ million) Trend Analysis by Taxonomy, 2018 to 2022
17.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2023 to 2033
17.3.1. By Service
17.3.2. By Product
17.3.3. By Expression System
17.3.4. By Company
17.3.5. By Scale of Operation
17.4. Attractiveness Analysis
17.4.1. By Service
17.4.2. By Product
17.4.3. By Expression System
17.4.4. By Company
17.4.5. By Scale of Operation
17.5. Drivers and Restraints - Impact Analysis
18. South Sales Analysis 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Size (US$ million) Trend Analysis by Taxonomy, 2018 to 2022
18.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2023 to 2033
18.3.1. By Service
18.3.2. By Product
18.3.3. By Expression System
18.3.4. By Company
18.3.5. By Scale of Operation
18.4. Attractiveness Analysis
18.4.1. By Service
18.4.2. By Product
18.4.3. By Expression System
18.4.4. By Company
18.4.5. By Scale of Operation
18.5. Drivers and Restraints - Impact Analysis
19. State Level Sales Analysis 2022 and Forecast 2033
19.1. Rio de Janeiro CMO/CDMO Analysis
19.1.1. Introduction
19.1.2. Sales Analysis and Forecast by Taxonomy
19.1.2.1. By Service
19.1.2.2. By Product
19.1.2.3. By Expression System
19.1.2.4. By Company
19.1.2.5. By Scale of Operation
19.2. São Paulo CMO/CDMO Analysis
19.2.1. Introduction
19.2.2. Sales Analysis and Forecast by Taxonomy
19.2.2.1. By Service
19.2.2.2. By Product
19.2.2.3. By Expression System
19.2.2.4. By Company
19.2.2.5. By Scale of Operation
19.3. Minas Geras CMO/CDMO Analysis
19.3.1. Introduction
19.3.2. Sales Analysis and Forecast by Taxonomy
19.3.2.1. By Service
19.3.2.2. By Product
19.3.2.3. By Expression System
19.3.2.4. By Company
19.3.2.5. By Scale of Operation
19.4. Bahia CMO/CDMO Analysis
19.4.1. Introduction
19.4.2. Sales Analysis and Forecast by Taxonomy
19.4.2.1. By Service
19.4.2.2. By Product
19.4.2.3. By Expression System
19.4.2.4. By Company
19.4.2.5. By Scale of Operation
19.5. Pioui CMO/CDMO Analysis
19.5.1. Introduction
19.5.2. Sales Analysis and Forecast by Taxonomy
19.5.2.1. By Service
19.5.2.2. By Product
19.5.2.3. By Expression System
19.5.2.4. By Company
19.5.2.5. By Scale of Operation
19.6. Rest of CMO/CDMO Analysis
19.6.1. Introduction
19.6.2. Sales Analysis and Forecast by Taxonomy
19.6.2.1. By Service
19.6.2.2. By Product
19.6.2.3. By Expression System
19.6.2.4. By Company
19.6.2.5. By Scale of Operation
20. Structure Analysis
20.1. Sales Analysis by Tier of Companies
20.2. Share Analysis of Top Players (%)
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Key Development Analysis
21.4. Branding and Promotional Strategies, by Key Manufacturers
21.5. Competition Deep Dive
21.5.1. Lonza AG
21.5.1.1. Overview
21.5.1.2. Product Portfolio
21.5.1.3. Key Financials
21.5.1.4. SWOT Analysis
21.5.1.5. Key Developments
21.5.1.6. Sales Footprint
21.5.1.7. Strategy Overview
21.5.2. Lonza AG
21.5.2.1. Overview
21.5.2.2. Product Portfolio
21.5.2.3. Key Financials
21.5.2.4. SWOT Analysis
21.5.2.5. Key Developments
21.5.2.6. Sales Footprint
21.5.2.7. Strategy Overview
21.5.3. Unither Pharmaceuticals
21.5.3.1. Overview
21.5.3.2. Product Portfolio
21.5.3.3. Key Financials
21.5.3.4. SWOT Analysis
21.5.3.5. Key Developments
21.5.3.6. Sales Footprint
21.5.3.7. Strategy Overview
21.5.4. Catalent Inc.
21.5.4.1. Overview
21.5.4.2. Product Portfolio
21.5.4.3. Key Financials
21.5.4.4. SWOT Analysis
21.5.4.5. Key Developments
21.5.4.6. Sales Footprint
21.5.4.7. Strategy Overview
21.5.5. Fagron
21.5.5.1. Overview
21.5.5.2. Product Portfolio
21.5.5.3. Key Financials
21.5.5.4. SWOT Analysis
21.5.5.5. Key Developments
21.5.5.6. Sales Footprint
21.5.5.7. Strategy Overview
21.5.6. Eurofarma
21.5.6.1. Overview
21.5.6.2. Product Portfolio
21.5.6.3. Key Financials
21.5.6.4. SWOT Analysis
21.5.6.5. Key Developments
21.5.6.6. Sales Footprint
21.5.6.7. Strategy Overview
21.5.7. Pfizer CentreOne
21.5.7.1. Overview
21.5.7.2. Product Portfolio
21.5.7.3. Key Financials
21.5.7.4. SWOT Analysis
21.5.7.5. Key Developments
21.5.7.6. Sales Footprint
21.5.7.7. Strategy Overview
21.5.8. Patheon N.V. (Thermo Fisher Scientific, Inc.)
21.5.8.1. Overview
21.5.8.2. Product Portfolio
21.5.8.3. Key Financials
21.5.8.4. SWOT Analysis
21.5.8.5. Key Developments
21.5.8.6. Sales Footprint
21.5.8.7. Strategy Overview
21.5.9. NUVISAN
21.5.9.1. Overview
21.5.9.2. Product Portfolio
21.5.9.3. Key Financials
21.5.9.4. SWOT Analysis
21.5.9.5. Key Developments
21.5.9.6. Sales Footprint
21.5.9.7. Strategy Overview
21.5.10. Societal CDMO
21.5.10.1. Overview
21.5.10.2. Product Portfolio
21.5.10.3. Key Financials
21.5.10.4. SWOT Analysis
21.5.10.5. Key Developments
21.5.10.6. Sales Footprint
21.5.10.7. Strategy Overview
21.5.11. Bio-Manguinhos
21.5.11.1. Overview
21.5.11.2. Product Portfolio
21.5.11.3. Key Financials
21.5.11.4. SWOT Analysis
21.5.11.5. Key Developments
21.5.11.6. Sales Footprint
21.5.11.7. Strategy Overview
21.5.12. Biotimize
21.5.12.1. Overview
21.5.12.2. Product Portfolio
21.5.12.3. Key Financials
21.5.12.4. SWOT Analysis
21.5.12.5. Key Developments
21.5.12.6. Sales Footprint
21.5.12.7. Strategy Overview
21.5.13. Pierre Fabre group
21.5.13.1. Overview
21.5.13.2. Product Portfolio
21.5.13.3. Key Financials
21.5.13.4. SWOT Analysis
21.5.13.5. Key Developments
21.5.13.6. Sales Footprint
21.5.13.7. Strategy Overview
21.5.14. Ajinomoto Co., Inc.
21.5.14.1. Overview
21.5.14.2. Product Portfolio
21.5.14.3. Key Financials
21.5.14.4. SWOT Analysis
21.5.14.5. Key Developments
21.5.14.6. Sales Footprint
21.5.14.7. Strategy Overview
22. Assumptions and Acronyms Used
Explore Healthcare Insights
View Reports
CMO/CDMO Industry Analysis in Brazil
